Best for
Mobile
How to buy Allergy Therapeutics shares
Own Allergy Therapeutics shares in just a few minutes.
Allergy Therapeutics plc is a drug manufacturers-specialty & generic business based in the UK. Allergy Therapeutics shares (AGY.LSE) are listed on the London Stock Exchange (LSE) and all prices are listed in pence sterling. Allergy Therapeutics employs 600 staff and has a trailing 12-month revenue of around £78.2 million.
How to buy shares in Allergy Therapeutics
- Choose a platform. If you're a beginner, our share-dealing table below can help you choose.
- Open your account. You'll need your ID, bank details and national insurance number.
- Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
- Search the platform for stock code: AGY in this case.
- Research Allergy Therapeutics shares. The platform should provide the latest information available.
- Buy your Allergy Therapeutics shares. It's that simple.
What's in this guide?
- Can I buy shares in Allergy Therapeutics?
- Allergy Therapeutics shares summary
- Compare share dealing platforms
- Is Allergy Therapeutics stock a buy or sell?
- Are Allergy Therapeutics shares over-valued?
- Allergy Therapeutics's financials
- How volatile are Allergy Therapeutics shares?
- Does Allergy Therapeutics pay a dividend?
- Other common questions
Allergy Therapeutics share price
Use our graph to track the performance of AGY stocks over time.Allergy Therapeutics shares at a glance
Information last updated 2021-01-23.
| Latest market close | N/Ap |
|---|---|
| 52-week range | 7p - 22p |
| 50-day moving average | 16.8044p |
| 200-day moving average | 15.5296p |
| Wall St. target price | 54.25p |
| PE ratio | 17.5 |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | 1.1p |
Invest in Allergy Therapeutics shares with 0% commission
Other fees may apply. Your capital is at risk.
- Unlimited trades, with no dealing charges or management fees
- If your trades get copied you can earn extra money
- Create an account today in a few minutes
Go to site
Capital at risk
Share dealing platform comparison
Table: sorted by promoted deals first
All investing should be regarded as longer term. The value of your investments can go up and down, and you may get back less than you invest. Past performance is no guarantee of future results. If you’re not sure which investments are right for you, please seek out a financial adviser. Capital at risk.
Is it a good time to buy Allergy Therapeutics stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Is Allergy Therapeutics under- or over-valued?
Valuing Allergy Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Allergy Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Allergy Therapeutics's P/E ratio
Allergy Therapeutics's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 18x. In other words, Allergy Therapeutics shares trade at around 18x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the FTSE 250 at the end of September 2019 (19.71). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Allergy Therapeutics's EBITDA
Allergy Therapeutics's EBITDA (earnings before interest, taxes, depreciation and amortisation) is £7.1 million.
The EBITDA is a measure of a Allergy Therapeutics's overall financial performance and is widely used to measure a its profitability.
Allergy Therapeutics financials
| Revenue TTM | £78.2 million |
|---|---|
| Operating margin TTM | 6.38% |
| Gross profit TTM | £58 million |
| Return on assets TTM | 4.03% |
| Return on equity TTM | 17.35% |
| Profit margin | 9.02% |
| Book value | 0.069p |
| Market capitalisation | £123.4 million |
TTM: trailing 12 months
Allergy Therapeutics share dividends
We're not expecting Allergy Therapeutics to pay a dividend over the next 12 months. However, you can browse other dividend-paying shares in our guide.
Allergy Therapeutics share price volatility
Over the last 12 months, Allergy Therapeutics's shares have ranged in value from as little as 7p up to 22p. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (LSE average) beta is 1, while Allergy Therapeutics's is 1.6261. This would suggest that Allergy Therapeutics's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Win £500 to get your trading started
Subscribe to trending stock alerts for a chance to win
Allergy Therapeutics overview
Allergy Therapeutics plc engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies, particularly to grasses, weeds, and trees, as well as diagnostics. Its products include Pollinex, Pollinex Quattro, Oralvac, Acarovac Plus, Acarovac MPL, Venomil, Synbiotics, Penicillin Diagnostics, and Peanut. The company also develops allergy vaccines for grass, tree, and house dust mite, as well as peanut allergy vaccines. It operates in Central Europe, Southern Europe, the United Kingdom, and internationally. Allergy Therapeutics plc was incorporated in 2004 and is headquartered in Worthing, the United Kingdom.
Frequently asked questions
More guides on Finder
-
How to buy Allergy Therapeutics shares
Learn more about Transportation and Logistics Systems’ recent performance and where you can invest in Transportation and Logistics Systems shares. We also run through some helpful rules of thumb for any investor.
-
How to buy Charlie’s Holdings shares
Learn more about Charlie’s Holdings’ recent performance and where you can invest in Charlie’s Holdings shares. We also run through some helpful rules of thumb for any investor.
-
How to buy Lemonade shares
Learn more about Lemonade’s recent performance and where you can invest in Lemonade shares. We also run through some helpful rules of thumb for any investor.
-
How to buy Unity Software shares
Learn more about Unity Software’s recent performance and where you can invest in Unity Software shares. We also run through some helpful rules of thumb for any investor
-
How to buy FuelCell Energy shares
Learn more about FuelCell Energy’s recent performance and where you can invest in FuelCell Energy shares. We also run through some helpful rules of thumb for any investor.
-
How to buy Allergy Therapeutics shares
Learn more about CloudCommerce’s recent performance and where you can invest in CloudCommerce shares. We also run through some helpful rules of thumb for any investor
-
How to buy Zomedica Pharmaceuticals shares
Ever wondered how to buy shares in Zomedica Pharmaceuticals? We explain how and compare a range of providers that can give you access to many brands, including Zomedica Pharmaceuticals.
-
How to buy YRC Worldwide shares
Ever wondered how to buy shares in YRC Worldwide? We explain how and compare a range of providers that can give you access to many brands, including YRC Worldwide.
-
How to buy Xeros Technology Group shares
Ever wondered how to buy shares in Xeros Technology Group? We explain how and compare a range of providers that can give you access to many brands, including Xeros Technology Group.
-
How to buy Xpediator shares
Ever wondered how to buy shares in Xpediator? We explain how and compare a range of providers that can give you access to many brands, including Xpediator.
Ask an Expert